Sector: Health Care
Director information for VERICEL CORP (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Alan Rubino | Executive Chairman | 71 | ["CEO/GM: Wealth of experience across biotechnology and pharmaceutical industries.","Marketing/Sales/Business Development: 24 years with Roche, executive committee member for ten years.","Operations: Provided enterprise-wide leadership over multiple functions."] | [] | 2026 |
| Dominick Colangelo | President and Chief Executive Officer | 62 | ["more than three decades of executive management experience","corporate development experience in the biopharmaceutical industry","executive positions in product development, pharmaceutical operations, sales and marketing, and corporate development","experience in acquisition, development, and commercialization of products","more than 25 years of executive management experience in the biopharmaceutical industry","served as President and CEO of Vericel for 13 years","significant accounting and finance background","experience in the acquisition, development and commercialization of products","experience in product development, pharmaceutical operations and corporate development"] | ["audit","compensation"] | 2026 |
| Dr. Wotton | President and Chief Executive Officer | ["President and Chief Executive Officer of Obsidian Therapeutics, Inc.","Founding President and Chief Executive Officer of Sigilon Therapeutics, Inc.","President and Chief Executive Officer of Ocata Therapeutics, Inc.","President and Chief Executive Officer of Antares Pharma, Inc.","Held senior level positions at Eurand International BV, Penwest Pharmaceuticals, Abbott Laboratories, and Merck, Sharp and Dohme","Member the board of directors of Cynata Therapeutics","Former member of the board of directors and Chairman of the compensation committee of Veloxis Pharmaceuticals A/S","Named Ernst & Young Entrepreneur of the Year for Life Sciences, New Jersey, in 2014"] | ["compensation committee","Emerging Companies Advisory Board of BIOTEC Canada"] | 2026 | |
| Heidi Hagen | Chairperson; Chief Technical Officer | 57 | ["More than 30 years of product development and leadership experience within the biopharmaceutical and medical device industries","Extensive operations experience in multiple commercial-stage biotechnology companies","Expertise in technical operations overseeing production operations for complex biologics"] | [] | 2026 |
| Jonathan Hopper | Chief Medical Officer | 63 | ["seasoned industry executive with previous experience as a surgeon and government regulator","Fellow of the Royal College of Surgeons of Edinburgh","senior medical officer at the UK’s Department of Health","M.B.A. (Health Executive) from the University of Keele","held various Global Medical Affairs and Clinical Development Executive roles for ConvaTec, Stryker, Osiris Therapeutics and Ferring Pharmaceuticals"] | [] | 2026 |
| Kevin McLaughlin | Chairperson of the Invivyd board’s audit committee and compensation committee | 69 | ["Audit committee financial expert","Oversight of financial statements","Experience with independent accountants","more than 40 years of operating management and financial experience spanning the biotech, high-tech and education industries","served for 11 years as the Senior Vice President, Chief Financial Officer and Treasurer of Acceleron Pharma Inc.","former member of the board of directors of Decibel Therapeutics","Co-founder, Chief Operating Officer and a director of Aptius Education, Inc."] | ["Audit Committee","compensation committee"] | 2026 |
| Lisa Wright | President and Chief Executive Officer | 51 | ["CEO/GM/Payer/Healthcare Operations","Accomplished healthcare executive","Strong strategic, operations and financial performance","Expertise in payer and provider aspects of the healthcare system","Deep understanding of healthcare economics and the full healthcare ecosystem"] | [] | 2026 |
| Paul Wotton, Ph.D. | 65 | [] | [] | 2026 | |
| Robert Zerbe, M.D. | Chairman of the Board | 75 | [] | ["Governance and Nominating Committee"] | 2026 |
